New medicines could eliminate uterine fibroid surgeries

Decisions Resources Group, a healthcare research and data company, suggests that the launch of new medicines could be a long-term management alternative to uterine fibroids surgeries over the next 10 years.

Novel selective progesterone receptor modulators (SPRMs) like Allergan/Gedeon Richter’s ulipristal, Bayer’s vilaprisan and Repros’s Proellex – and gonadotropin-releasing hormone (Gn-RH) antagonists like AbbVie’s elagolix, Myovant’s relugolix and ObsEva’s OBE-2109 – are projected to be effective medical alternatives to surgical procedures. Hysterectomies and myomectomies are the current long-term management of uterine fibroids.

Get the full story on our sister site, Medical Design & Outsourcing.

The post New medicines could eliminate uterine fibroid surgeries appeared first on MassDevice.